| Identification | Back Directory | [Name]
Bicyclo[3.1.0]hexane-2,6-dicarboxylic acid, 2-amino-, (1S,2S,5R,6S)- (9CI) | [CAS]
176199-48-7 | [Synonyms]
Eglumegad
Eglumetad
LY 354740
(1S,2S,5R,6S)-2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid
Bicyclo[3.1.0]hexane-2,6-dicarboxylic acid,2-amino-,(1S,2S,5R,6S)-
Bicyclo[3.1.0]hexane-2,6-dicarboxylicacid, 2-aMino-, [1S-(1a,2b,5a,6a)]-
Bicyclo[3.1.0]hexane-2,6-dicarboxylic acid, 2-amino-, (1S,2S,5R,6S)- (9CI) | [Molecular Formula]
C8H11NO4 | [MDL Number]
MFCD04113018 | [MOL File]
176199-48-7.mol | [Molecular Weight]
185.18 |
| Chemical Properties | Back Directory | [Melting point ]
270-271 °C | [Boiling point ]
376.4±32.0 °C(Predicted) | [density ]
1.569 | [storage temp. ]
Keep in dark place,Sealed in dry,2-8°C | [solubility ]
H2O : 6.33 mg/mL (34.18 mM; Need ultrasonic and warming) | [form ]
Powder | [pka]
2.06±0.40(Predicted) | [color ]
White to off-white | [InChI]
1S/C8H11NO4/c9-8(7(12)13)2-1-3-4(5(3)8)6(10)11/h3-5H,1-2,9H2,(H,10,11)(H,12,13)/t3-,4-,5-,8-/m0/s1 | [InChIKey]
VTAARTQTOOYTES-RGDLXGNYSA-N |
| Hazard Information | Back Directory | [Uses]
Treatment ofgeneral anxiety disorders and smoking cessation (metabotropic glutamate agonist). | [Definition]
ChEBI: Eglumetad is a L-alpha-amino acid. | [Biological Activity]
Highly selective and potent agonist of group II mGlu receptors (EC 50 values are 5.1 and 24.3 nM at mGlu 2 and mGlu 3 receptors respectively and > 100000 nM at mGlu 4 , mGlu 7 , mGlu 1a and mGlu 5a receptors). Displays antianxiety and antiaddictive activity in vivo . Orally and systemically active. | [in vivo]
Eglumegad (LY354740) (15 or 30 mg/kg, i.p.) has no effect on spatial working memory performance in Gria1 / or WT mice, and it has no effect on rewarded alternation testing with a short inter-trial interval in Gria1 / and WT mice at concentration of 30 mg/kg. Eglumegad (LY354740) (15 or 30 mg/kg, i.p.) reduces spontaneous locomotor activity in wild-type and Gria1 / mice[1]. Eglumegad (LY354740) (15 mg/kg, i.p.) dreases novelty-induced hyperlocomotion in naive GluA1-KO and pre-handled GluA1-KO males, but not in females. Eglumegad (LY354740) (15 mg/kg, i.p.) significantly reduces the increased c-Fos expression of GluA1-KO males to the level of WT males, but not in of females[3]. Eglumegad (LY354740) (10 mg/kg, i.p.) attenuates the immobilization stress-induced increase in BDNF mRNA expression in the rat mPFC[4]. | [IC 50]
mGluR2R: 5 nM (IC50); mGluR3R: 24 nM (IC50) | [storage]
+4°C |
|
|